Beijing Pharmaceutical Fair – National Pharmaceutical Trade Fair

The 2025 National Pharmaceutical Trade Fair (PHARMCHINA) successfully concluded its spring and autumn sessions. The 90th spring edition was held from May 21 to 23 at the China Import and Export Fair Complex in Guangzhou, while the 91st autumn edition took place from November 19 to 21 at the Nanjing International Expo Center. The spring show was themed “Quality Leads to a New Chapter,” whereas the autumn show centered on “Innovation as the Engine Driving High-Quality Development of the Industry Chain.” Co-organized by the China Pharmaceutical Industry Information Center and Reed Sinopharm, it stands as the annual highlight of the pharmaceutical sector.

In terms of scale, the spring exhibition spanned 170,000 square meters, integrated with API China and NHNE, bringing together 2,907 exhibitors from around the globe. It attracted over 200,000 professional visitors, including 32% from manufacturing and R&D institutions, 25% from pharmaceutical distribution, and 28% from retail pharmacies and distributors. Notably, attendance from grassroots medical institutions increased by 40% year over year. The autumn exhibition covered nearly 100,000 square meters, drawing more than 2,000 pharmaceutical companies and over 100,000 professional attendees. Concurrently, it hosted over 30 thematic conferences and forums, along with more than 10 special events.

This year’s fair featured numerous highlights, with innovative breakthroughs and internationalization emerging as central themes. The spring show introduced a dedicated “Innovation Meets the Future” launch zone, showcasing over 300 groundbreaking innovations in the pharmaceutical and healthcare sectors since 2023. In the inaugural Innovative Drug Launch Solutions Competition, AI-driven solutions were jointly evaluated alongside industry experts, resulting in 12 winning proposals. Meanwhile, international engagement accelerated markedly, with 25 overseas brands from 15 countries—including Germany’s STADA Group, Hetero, CaplinPoint, Maxmind, and Li’s Pharmaceutical—setting up independent pavilions. Events such as the “Asia Biopharmaceutical Industry Exchange Meeting” and the “China Pharmaceutical Internationalization and Innovation Forum” drew over 500 international guests, fostering multiple cooperation agreements between Chinese and foreign enterprises.

A vibrant area dedicated to the inheritance and innovation of traditional Chinese medicine sparked widespread interest in TCM culture. At the spring show, the “Fourth Traditional Chinese Medicine Heritage and Innovation Product Showcase” highlighted more than 50 new TCM products, including AI-powered four-diagnosis devices and Shengmai bagged tea. At the autumn show, the “High-Growth Channel Zone” adopted a three-dimensional integration model—exhibition, conference, and accompanying activities—to seamlessly connect market insights with resource alignment. The Seventh Strategic Development Forum for the TCM Industry delved deeply into topics such as TCM internationalization, pharmacoeconomics, and grassroots market expansion.

The Beijing delegation made consecutive appearances, underscoring the strength of the “Beijing Pharmaceuticals” brand. At the spring show, the Beijing delegation brought together 12 leading companies, including Chunfeng Pharmaceutical, Yadong Bio, Shuanglu Pharmaceutical, Xinghao Pharmaceutical, Jincheng Tail, Shengyong Pharmaceutical, Honglin Pharmaceutical, Saisheng Pharmaceutical, Shuguang Pharmaceutical, Shuangji Pharmaceutical, Jiacheng Bio, and Boran Pharmaceutical, collectively presenting chemical drugs, OTC products, biologics, and proprietary Chinese medicines. At the autumn show, more than 20 Beijing-based enterprises—including Tongrentang, Yuekang, Jialin, and Huaxia Shengsheng—participated, jointly promoting the brand philosophy of “Reassuring Quality Through Beijing Pharmaceuticals.”

Complementary events added richness, establishing a high-end platform for industry dialogue. The spring show hosted 32 conferences and forums, addressing issues such as supply-side reform in pharmaceutical distribution, the Innovative Drug Launch Solutions Competition, and the inheritance and innovation of traditional Chinese medicine. The autumn show featured the “China Pharmaceutical Distribution Industry Supply-Side Structural Reform Forum,” where leaders from the National Health Commission’s Pharmaceutical Administration Department explained key revisions to the Regulations on the Implementation of the Drug Administration Law and unveiled the “Fifteenth Five-Year Plan” Blue Book for the Pharmaceutical Distribution Sector. Jiangsu JinSili Pharmaceutical showcased its independently developed novel platelet aggregation function testing system based on four-concentration determination, drawing significant attention from the industry.

Attendees agreed that the National Pharmaceutical Trade Fair is not only an excellent platform for brand exposure and business matchmaking but also a critical hub for understanding trends in China’s pharmaceutical industry and exploring pathways toward innovation-driven growth and internationalization. From its origins as a drug allocation platform during the early days of reform and opening-up to its current role as the “Eastern Window” for global pharmaceutical innovation, PHARMCHINA has witnessed and propelled China’s pharmaceutical industry through a profound transformation—from generic‑drug dominance to an innovation‑driven era.